Blog

Contains articles from Dante and our partners discussing the latest research, publications, and updates about genome sequencing.
Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io
About Us

Dante Genomics launches doctor ordered, clinical whole genome sequencing in the U.S. in partnership with 1health.io

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Dante Genomics partnership with Al Farabi Medical Laboratories
About Us

Al Farabi Medical Laboratories and Dante Genomics announce global partnership for the delivery of Next Generation Sequencing Genomic Testing in the Kingdom of Saudi Arabia

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝
Dante Genomics will participate in The Canaccord Genuity MedTech Diagnostics and Digital Health and Services Forum 2022.
About Us

Dante Genomics to present at The Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Read More ➝